With healthcare costs under increasing downward pressure, providers are constantly striving to improve efficiency and access to care whilst reducing the number of unnecessary hospital visits. As shown by others, this can be aided by moving patient testing away from central laboratories and in to Point-of-Care (PoC) settings. To meet these demands, Atlas has developed the io® system, a unique PoC diagnostic platform for the ultra-rapid, inexpensive and accurate diagnosis of infectious diseases, based on a highly sensitive electrochemical detection technology.

Atlas Genetics Ltd today announces the appointment of Daniel Adlerstein as Director of Research & Development with immediate effect.

Mr Adlerstein brings product development expertise to Atlas after working in a variety of roles at Diasorin for over a decade.  Most recently, Daniel was Director of Product Development & Clinical Marketing at Biotrin (Diasorin Ireland), a fully owned subsidiary of Diasorin where he led the development of Liaison Iam, a novel instrument for multiplex quantitative isothermal amplification, launched in October 2012.  During his tenure, Daniel was responsible for building the molecular diagnostics programme and leading the development of amplification technologies and assays.  His team was responsible for the development of molecular tests and associated instruments in infectious diseases and oncology.

Formerly, Daniel held project management and research positions at Proneuron Biotechnologies, Algal Biotechnology Laboratory and for the Department of Organic and Industrial Chemistry at the University of Milan.  Daniel has a M.S. in Chemistry from the University of Milan and received his Ph.D in Chemistry from the Ben Gurion University in Israel and subsequently undertook postdoctoral research at Miami University in Ohio.

Dr John Clarkson, Chief Executive Officer of Atlas, commented: “Atlas is building a first class diagnostics Company.  The addition of Daniel brings a wealth of pertinent expertise in assay development in the infectious disease area and will be invaluable as we progress our first product towards market launch.”